Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baycol product liability litigation

Executive Summary

Bayer has received 5,700 lawsuits related to the Baycol withdrawal, "almost entirely" from the U.S., Chairman Werner Wenning says during Nov. 12 analysts meeting. "Many of the recently-filed complaints are simply copied from other complaints; for example, a single firm has filed 2,500 virtually identical complaints." Further, "where we have been able to evaluate preliminary facts obtained from plaintiffs through discovery, we have found that the majority of plaintiffs are not claiming that they were hospitalized or developed rhabdomyolysis - the side-effect that led to the withdrawal of Baycol." Bayer has settled 190 cases; more than 150 of the suits filed are class actions. Baycol (cerivastatin) was withdrawn in August 2001 (1"The Pink Sheet" Aug. 13, 2001, p. 4)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS040789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel